Results 141 to 150 of about 200,328 (301)

Individual Reimbursement Form

open access: yes, 2020
4-H Club Individual Reimbursement ...
Proudfoot, Chad N., Bonnett, Erika
core  

Twenty years of inhaler therapy: A nationwide drug utilization study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen   +5 more
wiley   +1 more source

Cost-Effectiveness and Budget Impact of Cardioform versus Amplatzer and Medical Therapy Alone for Patent Foramen Ovale Closure: A UK Payer Perspective

open access: yesClinicoEconomics and Outcomes Research
James R Bentham,1 Jet Neervoort,2 Timon Louwsma,2 Lambertus F Wolters,2 Julie Lyon,3 Erik J Landaas,4 Mitesh Nakum31Department of Paediatric Cardiology, Leeds General Infirmary, Leeds, UK; 2Asc Academics B.V, Groningen, the Netherlands; 3Department of ...
Bentham JR   +6 more
doaj  

Systemic menopausal hormone therapy treatment patterns in Danish women—A nationwide drug utilization study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Objectives This paper aims to describe the treatment patterns of contemporary systemic menopausal hormone therapy (MHT) in Denmark. Study design This study is a nationwide drug utilization study including an open cohort of all Danish women aged >40 years between 2000–2024.
Hannah K. Wood‐Kurland   +7 more
wiley   +1 more source

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink   +21 more
wiley   +1 more source

To Reimburse or not to Reimburse – That is the Question

open access: yesADC Review / Journal of Antibody-drug Conjugates, 2017
openaire   +1 more source

Incident low‐dose quetiapine use in adults newly diagnosed with depression in primary care: A nationwide register‐based study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to investigate the incidence of low‐dose quetiapine initiation and associated factors in adults newly diagnosed with depression in primary care. Methods We obtained medication dispensing records, primary and secondary care diagnoses and employment status for antipsychotic‐naïve individuals aged 16–65 newly diagnosed with ...
Laura Purra   +5 more
wiley   +1 more source

The impact of pharmacogenetic‐informed care on medication adherence and psychological factors associated with adherence: A narrative review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Improvement in medication adherence is often proposed as a potential advantage of pharmacogenetic‐guided prescribing over a traditional one‐size‐fits‐all approach. This paper provides a review of the published literature and presents the findings of studies that measure adherence to medication as an outcome of pharmacogenetic‐informed care, or that ...
Lucy Galloway   +2 more
wiley   +1 more source

Primary Care Reimbursement Service: Statistical analysis of claims and payments 2007

open access: yes, 2008
The Medical Card Scheme (GMS) and Community Drug Schemes are at the centre of the Primary Care Infrastructure of the Irish Health System. The net cost of the Schemes has more than doubled in just seven years, from €1.024 billion in 2001 to more than €
Finance Shared Services, Primary Care Reimbursement Service, Health Service Executive (HSE)
core  

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy